Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection

Sakurai, Kenichi; Zou, Jian-Ping; Torres, Naomi; Tschetter, Jolynne R.; Kim, H.-s; Shearer, Gene M.

doi:10.1016/s0041-1345(02)03560-1

Cited by 13 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…T cell activation is sensitive to local tryptophan concentrations, and lack of tryptophan blocks their proliferation [40] . By degrading tryptophan, IDO inhibits T cell proliferation and plays a role in autoimmunity and anti-inflammatory responses [41][42][43] . For example, Apoe -/-mice treated with the IDO inhibitor, 1-methyl-Trp, showed a significant increase in atherosclerotic lesions in the aortic arch and root of their hearts along with enhanced vascular inflammation [41] .…”

Section: Microenvironmentmentioning

confidence: 99%

Targeting amino acid metabolism in cancer growth and anti-tumor immune response

Ananieva

2015

WJBC

142

109

View full text Add to dashboard Cite

Recent advances in amino acid metabolism have revealed that targeting amino acid metabolic enzymes in cancer therapy is a promising strategy for the development of novel therapeutic agents. There are currently several drugs in clinical trials that specifically target amino acid metabolic pathways in tumor cells. In the context of the tumor microenvironment, however, tumor cells form metabolic relationships with immune cells, and they often compete for common nutrients. Many tumors evolved to escape immune surveillance by taking advantage of their metabolic flexibility and redirecting nutrients for their own advantage. This review outlines the most recent advances in targeting amino acid metabolic pathways in cancer therapy while giving consideration to the impact these pathways may have on the anti-tumor immune response. Core tip: Amino acid metabolism has been a focus of increased attention by cancer researchers and immunologists due to its importance for the metabolic reprogramming of proliferating cells. Many amino acid enzymes are described as immunosuppressive in the tumor microenvironment and targeted for cancer therapy. This review addresses the metabolic control of tumor progression in the context of anti-tumor immunity and discusses current and future therapeutic approaches. Special emphasis is given to the emerging role of branched chain amino acid metabolism in cancer and immunity highlighting some recent work by our research group. Ananieva E. Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem 2015; 6(4): 281-289 Available from:

show abstract

Section: Microenvironmentmentioning

confidence: 99%

Targeting amino acid metabolism in cancer growth and anti-tumor immune response

Ananieva

2015

WJBC

142

109

View full text Add to dashboard Cite

show abstract

“…The immunomodulatory function of IDO was first identified in the placenta, where it inhibits the rejection of fetal allografts (2,4). Subsequent studies documented that IDO inhibits T cell proliferation in vitro (4,5), promotes the survival of allografts (6)(7)(8), and ameliorates both experimental autoimmune encephalomyelitis (9) and trinitrobenzenesulfonic acid-induced colitis (10).…”

Section: Inhibition Of Nf-b and Induction Of Apoptosis Is Specific Tomentioning

confidence: 99%

3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis

Hayashi

Gong

et al. 2007

Proc. Natl. Acad. Sci. U.S.A.

157

123

View full text Add to dashboard Cite

show abstract

“…While it is tempting to speculate that Trp catabolism serves as an endogenous counter-regulatory mechanism to limit inflammation, evidence of its role in autoimmune diseases is limited. For instance, inhibition of IDO activity in an animal model of MS results in exacerbated disease [64,65]. Conversely, genetic ablation of IDO in mice does not result in overt, immediate autoimmune disease [41], indicating that the absence of IDO-mediated Trp catabolism per se is not sufficient to unleash autoimmunity.…”

Section: Trp Degradation As a Therapeutic Mechanism In Autoimmune Infmentioning

confidence: 99%

Tryptophan degradation in autoimmune diseases

Opitz

Wick

Steinman

et al. 2007

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Recent evidence points to tryptophan (Trp) degradation as a potent immunosuppressive mechanism involved in the maintenance of immunological tolerance. Both Trp depletion and downstream Trp catabolites (TCs) appear to synergistically confer protection against excessive inflammation. In this review, we give an overview of the immunosuppressive properties of Trp degradation with special focus on TCs. Constitutive and inducible Trp degradation in different cell types and tissues of human and murine origin is summarized. We address the influence of Trp degradation on different aspects of autoimmune disorders such as multiple sclerosis. Possible therapeutic approaches for autoimmune disorders targeting Trp degradation are presented, and key issues relevant for the development of such therapeutic strategies are discussed.

show abstract

Study of the effect of indoleamine 2,3-dioxygenase on murine mixed lymphocyte reactions and skin allograft rejection

Cited by 13 publications

References 22 publications

Targeting amino acid metabolism in cancer growth and anti-tumor immune response

Targeting amino acid metabolism in cancer growth and anti-tumor immune response

3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis

Tryptophan degradation in autoimmune diseases

Contact Info

Product

Resources

About